Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

Alice P. Chen, MD1; Shivaani Kummar, MD1,2; Nancy Moore, RN, MSN1; Lawrence V. Rubinstein, PhD1; Yingdong Zhao, PhD1; P. Mickey Williams, PhD1; Alida Palmisano, PhD1,4; David Sims, BS2; Geraldine O’Sullivan Coyne, MD, PhD1; Christina L. Rosenberger, PhD1; Mel Simpson, PhD2; Kanwal P. S. Raghav, MBBS, MD6; Funda Meric-Bernstam, MD6; Stephen Leong, MD1; Saiama Waqar, MBBS, MSC12; Jared C. Foster, PhD1; Mariam M. Konate, PhD5; Biswajit Das, PhD6; Chris Karlovich, PhD3; Chih-Jian Lih, PhD2; Eric Polley, PhD6; Richard Simon, DSc1; Ming-Chung Li, PhD1; Richard Piekarz, MD, PhD1; and James H. Doroshow, MD1,10

PURPOSE This trial assessed the utility of applying tumor DNA sequencing to treatment selection for patients with advanced, refractory cancer and somatic mutations in one of four signaling pathways by comparing the efficacy of four study regimens that were either matched to the patient’s aberrant pathway (experimental arm) or not matched to that pathway (control arm).

MATERIALS AND METHODS Adult patients with an actionable mutation of interest were randomly assigned 2:1 to receive either (1) a study regimen identified to target the aberrant pathway found in their tumor (veliparib with temozolomide or adavosertib with carboplatin [DNA repair pathway], everolimus [PI3K pathway], or trametinib [RAS/RAF/MEK pathway]), or (2) one of the same four regimens, but chosen from among those not targeting that pathway.

RESULTS Among 49 patients treated in the experimental arm, the objective response rate was 2% (95% CI, 0% to 10.9%). One of 20 patients (5%) in the experimental trametinib cohort had a partial response. There were no responses in the other cohorts. Although patients and physicians were blinded to the sequencing and random assignment results, a higher pretreatment dropout rate was observed in the control arm (22%) compared with the experimental arm (6%; P = .038), suggesting that some patients may have had prior tumor mutation profiling performed that led to a lack of participation in the control arm.

CONCLUSION Further investigation, better annotation of predictive biomarkers, and the development of more effective agents are necessary to inform treatment decisions in an era of precision cancer medicine. Increasing prevalence of tumor mutation profiling and preference for targeted therapy make it difficult to use a randomized phase II design to evaluate targeted therapy efficacy in an advanced disease setting.

INTRODUCTION Targeting therapy to the molecular characteristics of an individual’s tumor is a primary goal of precision cancer medicine.1-3 This approach hypothesizes that the presence of a mutation will render the tumor susceptible to an agent targeting that mutation. To explore this, we conducted a randomized, histology-agnostic clinical trial to examine whether patients with advanced, refractory cancer who had a tumor mutation in a gene in one of three signaling pathways (DNA repair, PI3K, or RAS/RAF/MEK) were more likely to derive clinical benefit if treated with regimens targeting that pathway (the experimental arm) than if they were treated with regimens that did not (the control arm). The treatment for each patient, whether experimental or control, was chosen from the same panel of four regimens: veliparib with temozolomide (TMZ), adavosertib with carboplatin, everolimus, or trametinib. For the experimental arm, the performance of each individual treatment cohort was to be compared with historical standards; the performance of the experimental arm, composed of all four targeted treatment cohorts, was to be compared with that of the control arm. Patients and treating physicians were blinded to the arm assignment and tumor sequencing data until the patient progressed.

MATERIALS AND METHODS Participants This study enrolled patients 18 years of age or older with histologically documented solid tumors whose disease had progressed following at least one line of standard therapy and/or for whom no standard treatment shown to improve survival was available.
**CONTEXT**

**Key Objective**
A molecular aberration in a patient’s tumor is expected to render the tumor susceptible to a drug targeting that aberration, but randomized, controlled, blinded phase II trials confirming the efficacy of this precision medicine approach are both sparse and challenging to design.

**Knowledge Generated**
Efficacy in patients with study-defined actionable mutations in the DNA repair, RAS/RAF/MEK, or AKT/PI3K/MTOR pathways either did not achieve the target objective response rate (trametinib or adavosertib with carboplatin) or indicated futility despite accrual challenges (everolimus or veliparib with temozolomide). Patients randomly assigned to the nontargeted control arm had a higher pretreatment dropout rate than the experimental arm, suggesting a preference for targeted therapy based on prestudy genetic profiling.

**Relevance**
The prevalence of genetic data makes it challenging to randomly assign patients to a nontargeted control arm. Better gene- and variant-specific biomarkers that predict response to drugs are needed for patients with cancer.

Patients were required to have measurable disease, be willing to undergo tumor biopsy to establish presence of a study-defined actionable mutation of interest (aMOI), and have tumor amenable to interventional radiology-guided percutaneous biopsy with a 16- to 18-gauge needle; excisional biopsy was allowed if indicated and evaluable. A Karnofsky performance status score ≥ 70% and adequate liver, kidney, and marrow function (as defined in the Data Supplement) were required. Previous anticancer therapy or surgery must have been completed at least 3 weeks prior to enrollment; patients with active brain metastases were ineligible. Patients who had prior treatment with any of the investigational agents were eligible to participate but were not assigned that same agent. Agent-specific eligibility criteria are included in the Data Supplement.

This trial was conducted under a National Cancer Institute (NCI)-sponsored Investigational New Drug Application with institutional review board approval. Protocol design and conduct followed all applicable regulations, guidelines, and local policies (ClinicalTrials.gov identifier: NCT01827384). The investigators obtained informed consent from each participant.

**Trial Design**
This was a multihistology, multicenter, randomized phase II study of four investigational drug regimens demonstrated to inhibit the DNA repair pathway, RAS/RAF/MEK pathway, or AKT/PI3K/MTOR pathway. Eligible patients with an aMOI detected were randomly assigned 2:1 to receive the recommended phase II dose of either (1) a predefined targeted regimen based on mutation status (experimental arm) or (2) a regimen, chosen from the four study regimens, that did not target their aMOIs (control arm). Treatment assignment was based on the presence of mutations in a panel of genes, each with a mutation frequency of > 5% in the Catalog of Somatic Mutations in Cancer database version 61, which were identified as direct or upstream targets for these drug combinations. The specific study aMOIs (Data Supplement) were selected on the basis of published functional evidence or implications for protein translation and pathway function; they were detected in patient samples via a Clinical Laboratory Improvement Amendments (CLIA) sequencing assay developed and validated by the Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research, as previously described. If more than one aMOI was detected for a patient randomly assigned to the experimental arm, selection of the targeted treatment was based on the higher allele frequency; if allele frequencies were within 15%, the patient was assigned to the targeted treatment cohort with the fewest patients enrolled (with the option to receive the other treatment regimen upon disease progression). If a patient randomly assigned to the control arm had multiple nontargeted treatment options, their regimen was chosen based on the proportions of treatment assignments on the experimental arm, so as to balance the two arms with respect to proportions receiving each of the four regimens.

For the purpose of assessing the primary end point of this trial, only response to the first regimen was used. Adverse events (AEs) were graded according to NCI Common Toxicity Criteria version 4.0 until March 31, 2018, when version 5.0 was implemented; all AEs were mapped to version 5.0 before the final analysis. Doses of all drugs were reduced for grade ≥ 3 nonhematologic and grade 4 hematologic toxicities (except lymphopenia or leukopenia in the absence of neutropenia). Patients were allowed up to two dose reductions before being taken off treatment. Radiographic evaluation was performed at baseline and every two cycles to assess tumor response based on the RECIST version 1.1.
Study Agents
Veliparib (ABT-888; NSC 737664), adavosertib (AZD1775; NSC 751084), trametinib (NSC 763093), and everolimus (NSC 733504) were supplied by the Division of Cancer Treatment and Diagnosis, NCI, under Collaborative Research and Development Agreements with AbbVie (North Chicago, IL), AstraZeneca (Cambridge, United Kingdom), GlaxoSmithKline (Brentford, United Kingdom), and Novartis (Basel, Switzerland), respectively. TMZ (NSC 362856) and carboplatin (NSC 241240) were obtained from commercial sources. Study drugs were administered at the recommended phase II doses and schedules (Data Supplement).

Statistical Study Design
The accrual ceiling for each regimen cohort of the experimental arm was set at 30 patients to discriminate between tumor response rates of 20% versus 5%. If at least four objective responses (at least 13%) were observed among the 30 patients, this regimen would have been considered promising for this mutation category. The design included

FIG 1. CONSORT diagram of the randomized portion of the NCI-MPACT study. Fifty percent of biopsied patients had an aMOI and were randomly assigned 2:1 to the experimental or control treatment arms, as outlined. Seven patients had an aMOI but could not be randomly assigned because they were ineligible for the targeted treatment (six patients: pancreatic cancer with an RAS mutation; one patient: unknown reason). Five patients had aMOIs in all three pathways and therefore had no control treatment available. These patients were not randomly assigned or considered evaluable for the study’s primary end point, but were offered targeted treatment (Data Supplement). All 70 patients who initiated treatment have come off study. aMOI, actionable mutation of interest; PD, progressive disease; TMZ, temozolomide.
an interim futility analysis; if no objective responses were observed among the initial 12 patients in each experimental cohort, the cohort was to be terminated early (with 54% likelihood under the null hypothesis), with 93% confidence that the response rate would be lower than the target 20% rate. This design yields at least 84% power to detect a true objective response rate of at least 20% and at least 0.94 probability of a negative result if the true objective response rate was no more than 5%. Four-month progression-free survival (PFS), defined as the time from random assignment to progression or death from any cause (whichever comes first), was evaluated as a secondary end point using Kaplan-Meier estimates and CIs calculated using Greenwood’s formula. Twelve or more instances of 4-month PFS (at least 40%) among the 30 patients in an experimental cohort was to be considered promising; this would occur with 90% likelihood if the true 4-month PFS rate is 50% (median PFS of 4 months) and with 5% likelihood if the true 4-month PFS rate is 25% (median PFS of 2 months).

RESULTS

Enrollment and Treatment Assignment

One hundred ninety-eight patients who met study eligibility criteria were enrolled from January 2014 to April 2018 (Fig 1, Table 1, Data Supplement), 108 (55%) of whom underwent a tumor biopsy procedure and ultimately had a study-actionable mutation detected (Fig 2A). Ninety-six (89%) of the patients with an identified aMOI were randomly assigned to a treatment arm (Fig 1, Data Supplement); patients without aMOIs or with insufficient tumor or DNA were taken off study without treatment.

The genes with highest frequency of study aMOIs were TP53 and KRAS (56% and 46% of patients with an aMOI, respectively) (Fig 2C, Data Supplement). All patients assigned to the two DNA repair pathway cohorts of the experimental arm had a TP53 mutation and 75% of patients assigned to the trametinib experimental cohort had a KRAS mutation. The majority of aMOIs were nonsynonymous single-nucleotide variants (Data Supplement).

Toxicity

Thirty (45%) of the 66 patients who received at least one dose of study agent(s) experienced an AE of grade 3 or greater that was considered at least possibly related to study treatment (Data Supplement). The toxicities reported were consistent with those previously observed for the study drugs. Five patients came off treatment because of toxicity. Seven patients died within 30 days of their last dose of study drugs but none of the on-study deaths were considered related or likely related to the study treatments.

Treatment Compliance

Interim analysis revealed unanticipated differences in compliance for patients who were assigned to targeted versus nontargeted therapy (Fig 3A). The overall percentage of patients assigned to the control arm who never initiated treatment was 47% (15/32), significantly higher than the rate for patients assigned to the experimental arm (23%; 15/64; \( P = .034 \), two-sided, by Fisher’s exact test). Evaluation of the reasons why patients came off study, as documented in the clinical database, reveals that a significantly higher percentage of the patients randomly assigned to the control arm chose not to start treatment (22% [7/32]) compared with the percentage of patients in the experimental arm who chose not to start treatment (6% [4/64]; \( P = .038 \), two-sided, by Fisher’s exact test).

TABLE 1. Patient Characteristics

| Characteristic                                | Number |
|----------------------------------------------|--------|
| Patients enrolled                           | 198    |
| Median age, years (range)                    | 60 (23-83) |
| Sex (female/male)                           | 109/89 |
| Median number of prior lines of therapy (range)* | 4 (1-12) |
| Patients with Karnofsky performance status (%) |        |
| 100                                          | 10     |
| 90                                           | 114    |
| 80                                           | 65     |
| 70                                           | 9      |
| Patients with an aMOI in a targeted pathway\(a\) |        |
| DNA repair                                    | 60     |
| PI3K                                         | 24     |
| RAS/RAF/MEK                                   | 62     |

Abbreviations: aMOI, actionable mutation of interest.
\(a\)Reported for patients who received at least one dose of study agent on NCI-MPACT.
\(b\)Reported for all patients with an aMOI detected on NCI-MPACT. Patients with an aMOI in more than one pathway are counted here for each affected pathway.
accrual to that cohort. The other cohorts were also closed because of the lack of activity. All patients are now off study.

Clinical Outcomes

Seventeen randomly assigned patients were treated in the control arm, none of whom experienced an objective response (0%; 95% exact binomial CI, 0% to 19.5%). There was one objective response among the 49 randomly assigned patients treated in the experimental arm (2%; 95% exact binomial CI, 0% to 10.9%). The planned comparison of objective response rate and PFS between the control arm and the experimental arm is precluded by the premature arm closures and the high dropout rate of the control arm. The Kaplan-Meier estimate of 4-month PFS among the randomly assigned and treated patients was 38.1% (95% CI, 26.0% to 56.0%) in the experimental arm and 22.7% (95% CI, 7.7% to 67.1%) in the control arm (Figs 4A and 4B, respectively). PFS events were experienced by 12/17 randomly assigned and treated patients in the control arm; among the patients randomly assigned to the experimental cohorts, PFS events were documented in 6 of 8 treated with everolimus, 20 of 20 treated with trametinib, 13 of 18 treated with adavosertib plus carboplatin, and 3 of 3 treated with veliparib plus TMZ. Caution must be used in comparing the individual experimental cohorts to the control arm as the restriction of an experimental cohort to a particular target may be prognostic of better (or worse) PFS. The estimate of 4-month PFS for the experimental everolimus cohort (50%) was significantly higher than the protocol-specified standard of 25% (P = .045; 95% CI, 22.5% to 100.0%) (Fig 4C), as was the 45% estimated 4-month PFS for the experimental trametinib cohort (P = .01; 95% CI, 27.7% to 73.1%) (Fig 4D). The estimate of 4-month PFS for the experimental adavosertib
plus carboplatin cohort (30.8%) was not found to differ significantly from the 25% standard ($P = .32$; 95% CI, 13.2% to 71.9%) (Fig 4E). None of the three patients in the experimental veliparib plus TMZ cohort were progression-free at 4 months (CI not provided because of small sample size).

Two patients experienced sustained stable disease (SD) for a noteworthy ≥24 cycles of targeted treatment (Fig 5). One patient with endometrial cancer and $PIK3CA$ H1047L and $PTEN$ R130* aMOIs received everolimus and experienced SD for 24 cycles before progressing. The other patient, a 52-year-old woman with low-grade ovarian cancer with an $NRAS$ Q61R aMOI, experienced SD for 27 cycles of trametinib treatment before her disease progressed. A 79-year-old male patient with melanoma and an $NRAS$ Q61R aMOI received six cycles of targeted trametinib and experienced a PR before progressing. In the experimental adavosertib plus carboplatin cohort, one patient with endometrial carcinoma and $TP53$ R213* and $PIK3CA$ C420R aMOIs had an unconfirmed PR before coming off treatment because of toxicity. None of the patients who crossed over at disease progression from the control arm to a targeted treatment or from one targeted treatment to another experienced clinical benefit on the crossover regimen (Data Supplement).

**DISCUSSION**

Highly effective, tailored therapy targeting specific genetic aberrations is a primary goal of precision medicine.\(^1,2\) Reports of exceptional responders, retrospective studies, and several nonrandomized trials indicate clinical benefit for genome-driven treatments, prompting optimism and discussion about the appropriate evidence framework for precision oncology.\(^3,8-24\) The results of our study, which was designed in 2012, highlight several important considerations for randomized precision oncology studies in the advanced disease setting that have evolved since then.\(^25-28\) With the greater prevalence of genetic tests and emphasis on precision medicine, it may be very challenging to randomly assign patients to a nontargeted control arm. Our data suggest that some patients and physicians may have had prior tumor mutation profile knowledge and, when randomly assigned to the control arm, appeared to show a bias favoring the presumed precision medicine approach, declining to participate in the study. This suggestion was anecdotally confirmed by conversations with some of the study investigators. The low dropout rate on the similarly designed SHIVA trial may be explained by having the patients randomly assigned to a physician’s choice control arm; results from the SHIVA trial also did not demonstrate the superiority of molecularly targeted agents over the control treatment.\(^25\) The results of the WINTHER and CoPPO trials, two nonrandomized studies, describe clinical benefit for a small number of patients with personalized treatment but the PFS-based end point was not met in either study.\(^29,30\) Our results are similar in that the two statistically evaluable experimental cohorts indicate that neither trametinib nor adavosertib plus carboplatin was more effective than standard therapy at achieving objective response when assigned to target NCI-MPACT-defined aMOIs in RAS/RAF/MEK or DNA repair pathways (eg, KRAS gain of function or TP53 loss of function mutations, respectively). Although presumed to be a superior, precision
FIG 4. Progression-free survival (PFS). Kaplan-Meier estimates of PFS for randomized NCI-MPACT patients who received at least one dose of study treatment on the (A) experimental arm (eight patients censored); (B) control arm, regardless of agent (five patients censored); (C) everolimus experimental cohort (two patients censored); (D) trametinib experimental cohort (zero patients censored); and (E) adavosertib plus carboplatin experimental cohort (five patients censored).
**FIG 5.** Clinical outcomes by NCI-MPACT aMOIs. Cycles of treatment, best response, and limited demographic information for each randomly assigned and treated patient. Each patient’s detected NCI-MPACT aMOIs are listed and color-coded to indicate the level of evidence that the mutation is susceptible to the assigned NCI-MPACT treatment (based on the information in the OncoKB and CIViC precision oncology knowledge bases at the time of writing). Where available, the results of whole exome sequencing are presented as the number of genetic alterations detected that are annotated in OncoKB as either oncogenic (with PM2 evidence of interest; OncoKB mutations). aMOI, actionable mutation of interest; CUP, cancer of unknown primary; dx, diagnosis; Illness, intercurrent illness required patient come off study; MPACT, molecular profiling-based assignment of cancer therapy; NR, no response; PD, progressive disease; PR, partial response; Prior Tx, number of lines of prior therapy; SD, stable disease; TMZ, temozolomide; Toxicity, study agent toxicity required patient come off study; Tx, treatment; uPR, unconfirmed partial response.
medicine approach, the lack of significant response on the experimental arm argues for need of better therapies and further validation. Extensive genetic sequencing and clinical trials evaluating broader aspects of pathway alterations may reveal additional information about actionable sensitivity markers.

The targeted treatment assignments in NCI-MPACT were made based on molecular aberrations that were expected to confer therapeutic sensitivity at the level of a signaling pathway. Since the trial’s initiation, the cancer research community has been engaged in an ongoing effort to identify gene- and variant-specific biomarkers that predict response to drugs. Retrospective review of two precision oncology knowledge bases, OncoKB and CIViC, suggests that there is little curated evidence to support many of the aMOI-drug associations targeted in the NCI-MPACT trial, which is consistent with the lack of clinical activity. For example, TP53 mutations, which were detected in every NCI-MPACT patient randomly assigned to a targeted DNA repair inhibitor cohort, are understood to be oncogenic but have remained largely undruggable. The experimental trametinib cohort is the exception in that for each RAS/MEK/ERK pathway aMOI that was detected, there is evidence curated in OncoKB or CIViC suggesting effective inhibition by trametinib. Notably, all three patients who were treated with trametinib to target an NRASQ61R mutation experienced clinical benefit, in line with published clinical evidence of MEK inhibitor activity in patients carrying an NRASQ61 mutation. Most of the patients treated in the experimental trametinib arm carried an aMOI in KRAS. Although there is preclinical support for treating KRAS aMOIs with an MEK inhibitor, the results of that approach were modest in this study, perhaps because of reported mechanisms of KRAS mutant resistance to ATP-noncompetitive MEK inhibitors. Furthermore, the presence of a therapy-targeted aMOI in a patient tumor does not indicate whether the aMOI is a driver or passenger mutation. In NCI-MPACT, the most frequently detected aMOIs—those in TP53 and KRAS—were detected in all four treatment cohorts and might have contributed to disease progression in cases where treatment was assigned to target an aMOI in a different pathway (eg, AKT/P13K/MTOR pathway). This may be one reason for the limited efficacy of targeted treatment in the everolimus cohort, where many patients had aMOIs in more than one signaling pathway. Treatment assignment in such cases was made based on the aMOI with the highest allele frequency but there is precedent for subclonal molecular alterations driving disease progression. Two of the three patients who tolerated everolimus treatment and had aMOIs confined to only the P13K pathway experienced prolonged SD (>10 cycles).

It is important to note that we were able to achieve a successful biopsy collection rate of >90%. Even with a turnaround time of ≤10 days for sequencing results, 19 biopsied patients (10%) progressed to the point of ineligibility or death before treatment initiation, reflecting the advanced disease status of this patient population. Biopsy sampling could not have identified spatially or temporally isolated tumor subclones that may have been driving tumor growth or conferring resistance in these patients; challenges that can be explored further in preclinical studies as can the presence of putative driver mutations in other signaling pathways.

We are completing the analysis of a preclinical study performed in parallel with the NCI-MPACT trial using xenograft models derived from the tumors of cancer patients to overcome the hurdles inherent to clinical investigations of molecularly targeted treatment response (manuscript in preparation). Our preliminary data suggest that functional in vivo evidence of activity in molecularly defined models should be the basis on which to evaluate clinical benefit of targeted agents in specified patient subgroups. Given the paradigm shift toward precision oncology, it is imperative that additional robust, comparative biomarker-targeted studies are conducted to identify new therapeutic options, inform personalized treatment decisions, and move the field forward.
commercial products, or organizations imply endorsement by the US Government.

AUTHOR CONTRIBUTIONS
Conception and design: Alice P. Chen, Shivaani Kummar, Lawrence V. Rubinstein, P. Mickey Williams, David Sims, Mel Simpson, Chih-Jian Lih, Eric Polley, Richard Simon, James H. Doroshow
Financial support: James H. Doroshow
Administrative support: P. Mickey Williams, Richard Piekarski, James H. Doroshow
Provision of study materials or patients: Shivaani Kummar, Geraldine O’Sullivan Coyne, Funda Meric-Bernstam, Stephen Leong, Chris Karlovich
Collection and assembly of data: Alice P. Chen, Shivaani Kummar, Nancy Moore, Yingdong Zhao, P. Mickey Williams, Alida Palmisano, David Sims, Christina L. Rosenberger, Mel Simpson, Kanwal P. S. Raghav, Funda Meric-Bernstam, Stephen Leong, Biswajit Das, Eric Polley, Richard Simon, James H. Doroshow
Data analysis and interpretation: Alice P. Chen, Shivaani Kummar, Nancy Moore, Lawrence V. Rubinstein, Yingdong Zhao, P. Mickey Williams, Alida Palmisano, David Sims, Geraldine O’Sullivan Coyne, Christina L. Rosenberger, Mel Simpson, Kanwal P. S. Raghav, Stephen Leong, Saiama Waqar, Jared C. Foster, Mariam M. Konaté, Biswajit Das, Chris Karlovich, Chih-Jian Lih, Eric Polley, Richard Simon, Ming-Chung Li, Richard Piekarski, James H. Doroshow
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Shivaani Kummar
Stock and Other Ownership Interests: PathomIQ, Arxeon
Consulting or Advisory Role: Corvus Pharmaceuticals, MedTree, Nodus Therapeutics, Genentech, ShangPharma Innovation, Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GMBH, Harbour BioMed, Cadila Pharmaceuticals
Research Funding: Bristol Myers Squibb, Dynavax Technologies, Pfizer, Loxo, Corvus Pharmaceuticals, Plexikon, Jounce Therapeutics, ADC Therapeutics, Advencen Laboratories, Incyte, Taiho Pharmaceutical, Bayer, Astex Pharmaceuticals, Seattle Genetics, Amgen, Genome & Company
Travel, Accommodations, Expenses: Bayer

Nancy Moore
Patents, Royalties, Other Intellectual Property: Nestle Nutrition
P. Mickey Williams
Research Funding: Illumina
Patents, Royalties, Other Intellectual Property: I was a co-inventor of the DLBCL cell of origin patent recently filed by the NIH
Kanwal P. S. Raghav
Consulting or Advisory Role: AstraZeneca, Bayer, Eisai, Daiichi Sankyo

Funda Meric-Bernstam
Employment: MD Anderson Cancer Center
Honoraria: Mayo Clinic, Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role: Genentech, Inflection Biosciences, Samsung Bioepis, Spectrum Pharmaceuticals, Aduro Biotech, OrigMed, Xencor, Debiopharm Group, Mersana, Seattle Genetics, Silverback Therapeutics, Immunomedics, IBM, Roche, PACT Pharma, eFFECTOR Therapeutics, Jackson Laboratory for Genomic Medicine, Kolon Life Sciences, Parexel International, Pfizer, Tyra Biosciences, Zymeworks, Puma Biotechnology, Zentalis, Alkermes
Speakers’ Bureau: Chugai Pharma
Research Funding: Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer, Aileron Therapeutics, Puma Biotechnology, Cytori Therapeutics, Jounce Therapeutics, Zymeworks, Curis, Pfizer, eFFECTOR Therapeutics, Abbvie, Boehringer Ingelheim, Guardant Health, Daiichi Sankyo, GlaxoSmithKline, Seattle Genetics, Millennium
Travel, Accommodations, Expenses: Taiho Pharmaceutical, Beth Israel Deaconess Medical Center

Stephen Leong
Employment: Merck Sharp & Dohme
Stock and Other Ownership Interests: Antares Pharmaceuticals, Spectrum Pharmaceuticals
Consulting or Advisory Role: Bristol Myers Squibb
Research Funding: Deciphera, Karyopharm Therapeutics, Bristol Myers Squibb, Lilly
Travel, Accommodations, Expenses: Genentech/Roche

Saiama Waqar
Research Funding: Spectrum Pharmaceuticals, Lilly, Pfizer, Genentech/Roche, Daiichi Sankyo, Newlink Genetics, EMD Serono, Puma Biotechnology, Novartis, Xcovery, Synernore Biologics, Celgene, Vertex, Bristol Myers Squibb, Stemcentrx, Hengrui Therapeutics, Checkpoint Therapeutics, Ignyta, AstraZeneca, ARIAD, Roche, Merck
Biswaajit Das
Research Funding: Illumina

Chris Karlovich
Stock and Other Ownership Interests: Clovis Oncology
Research Funding: Illumina
Travel, Accommodations, Expenses: Illumina

Chih-Jian Lih
Employment: Exelixis
Stock and Other Ownership Interests: Exelixis
Eric Polley
Research Funding: GRAIL
Richard Simon
Consulting or Advisory Role: AbbVie, Amgen, Janssen, Bristol Myers Squibb, Pfizer, Onco-Nano
Travel, Accommodations, Expenses: Amgen

No other potential conflicts of interest were reported.

ACKNOWLEDGMENT
The authors thank Naoko Takebe, Elad Sharon, Howard Streicher, Sheila Prindiville, and Barbara Conley (National Cancer Institute) for their clinical contributions, and Robin Harrington, Courtney Bouk, and Keshay N. Harper (Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research) for their excellent technical assistance.
40. Dai X, Xia H, Zhou S, et al: Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. Cancer Lett 442:202-212, 2019
41. Hatzivassiliou G, Haling JR, Chen H, et al: Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501:232-236, 2013
42. Sun C, Hobor S, Bertotti A, et al: Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep 7:86-93, 2014
43. Tannock IF, Hickman JA: Limits to personalized cancer medicine. N Engl J Med 375:1289-1294, 2016
44. McGranahan N, Swanton C: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27:15-26, 2015
45. Brady SW, McQuerry JA, Qiao Y, et al: Combating subclonal evolution of resistant cancer phenotypes. Nat Commun 8:1231, 2017
46. Landau DA, Carter SL, Stojanov P, et al: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-726, 2013
47. Rossi D, Khiabanian H, Spina V, et al: Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123:2139-2147, 2014
48. Hong MKH, Macintyre G, Wedge DC, et al: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 6:6605, 2015
49. Ferry-Galow KV, Datta V, Makhlouf HR, et al: What can be done to improve research biopsy quality in oncology clinical trials? J Oncol Pract 14:e722-e728, 2018
50. Schmitt MW, Loeb LA, Salk JJ: The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol 13:335-347, 2016
51. Lipinski KA, Barber LJ, Davies MN, et al: Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer 2:49-63, 2016